What is iQure Pharma?
iQure Pharma operates at the intersection of advanced pharmacology and neurology, specializing in the development of small molecule therapies designed to mitigate excitotoxicity. The company's flagship asset, iQ-007, represents a significant advancement in therapeutic innovation, currently undergoing Phase 1 clinical trials. By targeting the primary glutamate transporter, iQure Pharma aims to prevent neuronal damage, a critical mechanism in the progression of various CNS-related pathologies. Their operational model relies on a robust network of academic and institutional collaborations, which serves to validate their scientific methodology and accelerate the maturation of their therapeutic pipeline. This strategic focus on glutamate homeostasis provides a distinct competitive advantage in the crowded landscape of neuro-pharmacology.
How much funding has iQure Pharma raised?
iQure Pharma has raised a total of $2.5M across 3 funding rounds:
Series A
$600K
Other Financing Round
$1.2M
Stock/Share Issuance
$650K
Series A (2022): $600K with participation from Keiretsu Forum Mid-Atlantic
Other Financing Round (2023): $1.2M, investors not publicly disclosed
Stock/Share Issuance (2026): $650K, investors not publicly disclosed
Key Investors in iQure Pharma
Keiretsu Forum Mid-Atlantic
A prominent angel investor network that provides early-stage capital and due diligence support to emerging growth companies.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for iQure Pharma?
With the recent influx of capital, iQure Pharma is well-positioned to accelerate its clinical development roadmap. The primary objective remains the successful progression of iQ-007 through clinical milestones, which will be pivotal for future regulatory filings and potential commercialization strategies. Furthermore, the company is expected to leverage this financial runway to expand its research into additional CNS indications, potentially diversifying its portfolio beyond epilepsy. As the firm transitions from early-stage development to more advanced clinical phases, the focus will likely shift toward optimizing manufacturing processes and strengthening intellectual property protections to ensure long-term market viability in the global biotech ecosystem.
See full iQure Pharma company page
